NCT06671431

Brief Summary

Recent studies addressing the role of adjuvant chemotherapy in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on tumor location and resectability. Therefore, the aim of this study was to investigate the role of AC in distal cholangiocarcinoma, a common tumor subtype of CCA.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
578

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2000

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2000

Completed
22 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
2.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 31, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 4, 2024

Completed
Last Updated

November 4, 2024

Status Verified

October 1, 2024

Enrollment Period

22 years

First QC Date

October 31, 2024

Last Update Submit

October 31, 2024

Conditions

Distal CholangiocarcinomaAdjuvant Chemotherapy

Outcome Measures

Primary Outcomes (1)

  • Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma

    From January 2000 to December 2021

Interventions

Adjuvant chemotherapyDRUG

Adjuvant chemotherapy with or without radiotherapy

Eligibility Criteria

Age19 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with distal cholangiocarcinoma who underwent curative surgery

You may qualify if:

  • Patients with distal cholangiocarcinoma who underwent surgery

You may not qualify if:

  • Who underwent neoadjuvant treatment
  • Who underwent R2 resection
  • Non-adenocarcinoma patients in final pathology report
  • Insufficient data
  • Death within 90days of surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Chemotherapy, Adjuvant

Intervention Hierarchy (Ancestors)

Combined Modality TherapyTherapeuticsDrug Therapy

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 31, 2024

First Posted

November 4, 2024

Study Start

January 1, 2000

Primary Completion

December 31, 2021

Study Completion

October 1, 2024

Last Updated

November 4, 2024

Record last verified: 2024-10